Marketing authorization is not the end of regulatory responsibility. For many pharmaceutical products, approval creates a new layer of work that may continue for months or years.
A Marketing Authorization Holder (MAH) may need to complete additional studies, provide safety or efficacy data, update risk-management activities, meet CMC-related conditions, respond to health-authority requests, submit agreed reports or implement regulatory actions arising from new evidence. Collectively, these activities are often described operationally as Regulatory Commitments. But that label needs care. Different jurisdictions use different legal and procedural terminology, and not every activity after approval has the same regulatory status.
For example, US-FDA distinguishes legally required postmarketing requirements (PMRs) from postmarketing commitments (PMCs) that a sponsor has agreed to undertake but that are not required under statute or regulation. EMA uses its own framework of post-authorisation measures, including specific obligations, Annex II conditions, additional pharmacovigilance activities, legally binding measures and recommendations. For MAHs operating across multiple markets, effective regulatory commitments management therefore requires more than maintaining a list of due dates.
What is Post-Authorization Regulatory Commitments?
Post-Authorization Regulatory Commitments are regulatory activities, studies, data submissions or other measures that remain outstanding or arise after a medicinal product has been authorised.
They can originate from several points in the product lifecycle, including:
- the initial marketing-authorisation decision.
- approval conditions.
- health-authority correspondence.
- assessment outcomes.
- risk-management plans.
- pharmacovigilance procedures.
- post-authorisation studies.
- manufacturing or quality commitments.
- inspections and related CAPAs.
- safety-signal assessments.
- subsequent variations or lifecycle procedures.
In the US, PMRs and PMCs are legally distinct. FDA defines PMRs as studies or clinical trials required under regulations, while PMCs are studies or trials that an applicant has agreed to conduct but that are not legally required in the same way.
In the EU centralised system, EMA classifies post-authorisation measures according to their legal framework. These can include specific obligations, Annex II conditions, additional pharmacovigilance activities in the RMP, legally binding measures and recommendations.
For MAH regulatory obligations, that classification matters because it can determine:
- whether an activity is legally binding.
- how its deadline is managed.
- which regulatory procedure applies.
- how changes to the commitment must be requested.
- what evidence is needed for completion.
- what can happen if the obligation becomes overdue.
A strong commitment-management system therefore records not only what must be done, but also why it must be done and under which regulatory framework.
Why Post-Approval Commitments Are Difficult to Manage Globally
A single commitment is usually manageable. The challenge begins when one product becomes five products, one country becomes forty markets, and one regulatory team becomes a network of global and local functions.
The same underlying study may support obligations in several countries. A safety finding may trigger an RMP change in one region, product-information updates in others and separate local regulatory actions elsewhere. A manufacturing commitment may affect several applications that reference the same site.
This creates three types of complexity:
Regulatory complexity
Different authorities may use different terminology, procedures, milestones and closure expectations.
An FDA PMR should not simply be managed as though it were equivalent to an EMA-specific obligation. The scientific work may overlap, but the regulatory pathway and evidence of fulfilment may differ.
Operational complexity
Commitments can depend on Regulatory Affairs, Pharmacovigilance, Clinical, Medical Devices, Quality, CMC, Manufacturing, Biostatistics & other teams.
The regulatory owner may therefore depend on several functions that do not share the same project timelines or systems.
Portfolio complexity
The same evidence may affect:
- multiple products.
- several indications.
- more than one manufacturing site.
- multiple marketing authorisations.
- several markets.
- future variations and labeling changes.
This is why global regulatory commitment management eventually becomes a data-governance problem. The organisation needs to know not only which obligations are open, but how they relate to the broader product lifecycle.
The Post-Authorization Commitment Lifecycle
A practical commitment-management model should follow the regulatory obligation from the moment it is created until formal closure.
- Capture
Record the obligation as soon as it appears in an approval letter, assessment outcome, authority request, RMP, inspection correspondence or other authoritative source.
- Classify
Identify its regulatory basis
- legally required
- voluntarily agreed
- a specific obligation
- an Annex II condition
- an additional pharmacovigilance activity
- an authority recommendation
- a CMC commitment
- an inspection-related action
- another jurisdiction-specific obligation
Classification prevents teams from treating every commitment as procedurally identical.
- Assess
Determine:
- deliverables
- regulatory procedure
- required evidence
- dependencies
- milestones
- due date
- potential product and market impact.
- Assign
Give the commitment one accountable owner, even when several functions contribute to delivery.
- Monitor
Track both regulatory deadlines and operational milestones.
- Submit
Provide the required report, study result, variation, response or other deliverable through the appropriate regulatory route.
- Follow the authority assessment
Submission is not necessarily closure. Authorities may request additional information, require another regulatory action or determine that the commitment remains outstanding.
- Close
Close the record only when the applicable regulatory framework provides sufficient evidence that the obligation has been fulfilled, released or otherwise formally concluded.
This lifecycle is the foundation of reliable post-approval commitment management.
What MAHs Should Track for Every Regulatory Commitment
A commitment register should be detailed enough to support compliance but structured enough to remain usable.
At minimum, every commitment record should contain:
If an internal project slips by three months, replacing the original regulatory deadline in a tracker does not change the obligation agreed with the regulator. Good regulatory commitments management preserves that distinction.
How to Assign Ownership Across Regulatory, PV, Clinical and CMC Teams
Regulatory commitments are often cross-functional, but accountability cannot be cross-functional in the same way. Consider a post-authorisation safety study.
Pharmacovigilance may define the safety objective. Clinical or epidemiology teams may manage the study. Biostatistics may analyse the results. Medical Writing may prepare the report. Regulatory Affairs may determine how and when the results must be submitted. But one person should remain accountable for ensuring that the regulatory obligation itself progresses from creation through closure.
A scalable ownership model separates three roles:
Regulatory owner
Responsible for the commitment record, authority expectations, regulatory timeline, submission pathway and closure status.
Functional owner
Responsible for generating the scientific, clinical, pharmacovigilance solutions, quality or CMC deliverable.
Contributors
Responsible for individual activities required to complete the work. This prevents one of the most common weaknesses in MAH regulatory obligations management: several teams believing another function owns the final regulatory step.
For global commitments, ownership should also distinguish between:
- global regulatory accountability.
- regional regulatory coordination.
- local-market execution.
Local teams should not create duplicate scientific work simply because several countries require actions based on the same global evidence.
How to Track Commitment Deadlines and Milestones
Tracking only the final due date creates false confidence. Suppose a final clinical study report is due in September 2028. The commitment may appear low risk in early 2027.
But if the protocol must be finalised by March 2027, the study started by June, recruitment completed by December and analysis completed the following year, the first meaningful compliance risk appears long before September 2028.
Every major commitment should therefore have:
Regulatory deadline
The authority-agreed or legally applicable due date.
Internal target date
A deliberately earlier operational deadline.
Critical milestones
Intermediate events required to achieve the final obligation.
Risk status
For example:
- On track
- Watch
- At risk
- Delayed
- Submitted / awaiting assessment
- Fulfilled
- Released
- Closed
Where an authority provides formal status terminology, internal systems should preserve it rather than replacing it with generic project-management language.
FDA, for example, uses seven PMR/PMC status categories: pending, ongoing, delayed, terminated, submitted, fulfilled and released. FDA specifically distinguishes “submitted” from “fulfilled.”
FDA also requires annual status reporting for open applicable PMRs/PMCs until the Agency notifies the applicant that they have been fulfilled or released. That illustrates why milestone tracking is not simply project management. It is part of maintaining an accurate regulatory status.
What Happens When a Regulatory Commitment Is Delayed?
A delay should never be treated as one universal regulatory event.
The consequences depend on:
- jurisdiction.
- legal basis.
- type of obligation.
- reason for delay.
- stage of the commitment.
- impact on benefit-risk.
- whether the authority accepted a revised timeline.
For FDA PMRs/PMCs, “delayed” is a defined status. FDA evaluates progress against the original schedule, and delays can occur during recruitment, analysis or final-report submission.
For a legally required PMR, missing milestones can carry more significant consequences than a delay to a voluntary commitment. FDA has taken enforcement action where a sponsor failed to meet a required PMR milestone without demonstrating good cause.
The EU position is similarly dependent on the regulatory category. EMA’s current post-authorisation guidance states that overdue post-authorisation measures or non-compliance may trigger further assessment and actions. Depending on the circumstances, these can include communication with the MAH, an oral explanation, inspection, or regulatory action with a view to varying, suspending or revoking the marketing authorisation service. Certain non-compliance can also lead to infringement procedures.
For MAHs, the practical response to a potential delay should therefore be:
- identify the affected regulatory obligation.
- determine its legal and procedural status.
- document the cause.
- assess impact on safety, efficacy, quality and benefit-risk where relevant.
- determine whether authority communication or a formal regulatory procedure is required.
- propose a realistic recovery plan.
- preserve the original commitment and approved timeline in the regulatory record.
How MAHs Prove a Commitment Has Been Fulfilled
One of the most important rules in Post-Authorization Compliance is: Submitted does not always mean fulfilled.
FDA makes the distinction explicit. A PMR or PMC can be classified as submitted once the final study report has been provided, while fulfilled means FDA has reviewed the final report and determined that the terms of the requirement or commitment have been met. “Released” is a separate closure state in which FDA informs the applicant that it no longer needs to conduct the study because it is no longer feasible or would no longer provide useful information.
EMA uses different terminology but applies a similarly important principle. A post-authorisation measure may remain unfulfilled if further clarification or additional data are required. Even where a measure itself is considered fulfilled, the assessment may identify follow-up regulatory action such as a variation.
MAHs should therefore retain closure evidence such as:
- formal authority correspondence.
- regulatory decision or assessment outcome.
- confirmation of fulfilment.
- release from the obligation.
- approved variation where required.
- updated authorization conditions.
- final accepted RMP or product information where relevant.
How Regulatory Technology Helps Manage Post-Approval Commitments
Regulatory technology cannot determine whether an MAH has complied with an obligation. It can, however, make compliance substantially easier to govern. This allows teams to replace isolated spreadsheets with a connected view of the regulatory lifecycle.
Useful capabilities include:
- centralized commitment registers.
- automated deadline alerts.
- ownership assignment.
- milestone tracking.
- role-based access.
- audit trails.
- source-document links.
- portfolio dashboards.
- market- and product-level views.
- overdue and at-risk reports.
- dependency tracking.
- reporting of submitted-but-not-closed commitments.
Technology becomes particularly valuable when an MAH needs answers such as:
- Which commitments are due in the next 90 days?
- Which are delayed?
- Which open obligations rely on the same global study?
- Which commitments have been submitted but remain under assessment?
- Which obligations could trigger a variation or labeling update?
- Which markets depend on the same CMC deliverable?
- Who owns the next regulatory action?
DDReg’s VITALIC LC, for example, is designed to maintain product- and market-level lifecycle information, including variations, renewals and post-approval commitments, with ownership and alert functionality. The technology is not the compliance strategy, it is the infrastructure that makes global regulatory commitment management visible and governable at scale.
Global vs Local Post-Authorization Obligations
One of the hardest parts of multinational commitment management is deciding what should be governed globally and what must remain market specific. A useful model separates commitments into four categories.
Global evidence commitments
These involve evidence that can potentially support several jurisdictions, such as:
- global clinical-study results.
- long-term safety data.
- global CMC validation activities.
- certain manufacturing data.
- core benefit-risk analyses.
The evidence should be governed centrally wherever possible.
Regional obligations
These arise from a regional regulatory framework, such as an EU post-authorisation measure or RMP-related activity.
Local obligations
These are specific to one authority, national procedure, marketing authorisation or local regulatory condition.
Linked obligations
These are separate local or regional commitments that rely on the same underlying evidence. This last category is particularly important.
If a single global study supports obligations in the US, EU and several other markets, there may still be multiple regulatory submissions and closure decisions. But there should not be multiple disconnected scientific projects.
The scalable model is:
Generate evidence globally.
Map obligations locally.
Submit according to each market’s requirements.
Track closure independently.
2026 Trends in Post-Authorization Compliance
Post-authorisation regulation in 2026 is moving toward more structured lifecycle control rather than simple deadline tracking.
- Greater procedural integration between commitments and lifecycle changes
EMA’s post-authorisation guidance continues to reinforce the relationship between RMP changes, post-authorisation measures and formal variation procedures. Its RMP guidance was updated in March and July 2026, including clarification around variation classification and management of RMP changes.
For MAHs, the implication is clear: commitment completion increasingly needs to be understood in the context of the broader regulatory procedure it may trigger.
- More structured regulatory status data
FDA maintains a searchable PMR/PMC database and a downloadable dataset that is updated quarterly. The database identifies open and recently closed PMRs/PMCs and provides formal status information.
This reinforces the importance of maintaining internal regulatory data that can be reconciled against authority records.
- Formal digital handling of post-authorisation procedures
EMA instructs MAHs to use the IRIS platform for managing post-authorisation measures after the original submission, while IRIS and the submission gateway continue to serve different functions.
Commitment management is therefore becoming increasingly connected to structured digital regulatory workflows.
- Stronger focus on RMP lifecycle governance
EMA guidance makes clear that RMPs may need to be updated during the product lifecycle when significant new information or regulatory procedures affect the risk-management strategy.
This means pharmacovigilance commitments cannot be managed independently from variations, product information and other lifecycle activities.
- Central visibility is becoming more important as portfolios scale
This is primarily an operational trend rather than a new legal requirement.
Global MAHs increasingly need systems capable of linking commitments across products, markets and functions because the regulatory obligation may be local while the evidence required to satisfy it is global.
In 2026, effective regulatory commitments management is therefore becoming less about maintaining a master spreadsheet and more about maintaining reliable regulatory relationships between data, documents, submissions and authority decisions.
Post-Authorization Commitment Management Checklist for MAHs
Before considering a commitment-management process controlled, MAHs should be able to answer yes to the following questions.
Commitment identification
- Have all open Regulatory Commitments been captured?
- Is each commitment linked to its authoritative regulatory source?
- Is its legal or procedural category recorded correctly?
Ownership
- Is one regulatory owner accountable for every commitment?
- Are supporting PV, Clinical, CMC, Quality and Medical teams identified?
- Are global and local responsibilities clearly separated?
Deadlines
- Is the original regulatory deadline preserved?
- Are intermediate milestones tracked?
- Is there an earlier internal target?
- Are overdue and at-risk commitments automatically visible?
Regulatory impact
- Are dependencies on variations, RMP updates, drug labeling, CMC or safety activities documented?
- Can one global commitment be linked to several local obligations?
- Is potential downstream impact assessed when results become available?
Submission
- Is the required regulatory procedure known before the deliverable becomes due?
- Is every submitted package linked to the commitment record?
- Are authority questions and follow-up requests tracked?
Closure
- Is “submitted” kept separate from “fulfilled”?
- Is formal closure evidence retained?
- Are follow-up regulatory actions completed before the record is fully closed?
Governance
- Can management see upcoming commitments across the complete portfolio?
- Can teams identify delayed, submitted and unclosed obligations quickly?
- Can the commitment history be reconstructed without relying on individual inboxes?
Conclusion
Approval changes the type of regulatory work an MAH perform, it does not remove the work. The strongest Post-Authorization Compliance model treats every commitment.
That becomes increasingly important as portfolios expand globally. One study may generate several regulatory actions. One safety finding may affect multiple markets. One manufacturing commitment may trigger several lifecycle submissions. Effective global regulatory commitment management creates the structure required to coordinate those relationships without losing local regulatory accountability.
For pharmaceutical companies managing complex post-approval portfolios, DDReg’s Post Approval Life Cycle Management services support regulatory changes, variations, labeling services and quality-related lifecycle activities, while VITALIC LC provides a connected framework for maintaining registration and post-approval information across products and markets. The goal is not simply to remember every deadline, it is to ensure every regulatory obligation remains visible until there is defensible evidence that it is genuinely closed
Frequently Asked Questions
No. Submission and closure should be treated separately. FDA explicitly distinguishes “submitted” from “fulfilled”; fulfilment occurs after FDA reviews the final report and determines that the terms have been met. EMA may also require further clarification, additional data or follow-up regulatory action before a post-authorisation measure is considered fully resolved.
The MAH should determine the commitment's legal basis, document the reason for delay, evaluate regulatory and benefit-risk implications, establish a recovery plan and determine whether authority communication or a formal procedure to modify the commitment is required. An internal deadline should never simply replace the regulator-agreed date without the appropriate regulatory process.
The scientific evidence should be governed centrally where appropriate, while each jurisdiction-specific obligation, submission route, deadline and closure decision should be tracked separately. This allows global reuse without assuming that one authority's closure automatically closes the obligation elsewhere.
Regulatory technology can centralize commitment records, ownership, deadlines, milestones, documents, alerts and closure evidence. It can also connect commitments to products, markets, authorizations and lifecycle events, giving MAHs a portfolio-wide view of open and at-risk Post-Authorization Regulatory Commitments.
Regulatory commitments management focuses specifically on defined obligations, agreed deliverables, milestones, authority interactions and closure. Post-approval lifecycle management is broader and can also include variations, renewals, manufacturing changes, labeling updates, transfers and other changes required to maintain an authorized product.